A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
Recruitment status was Active, not recruiting
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
|Study Design:||Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment